Title: The role of brain 5-HT1A receptors in the actions of antidepressant drugs

**Abstract**

Major depression is a severe and heterogeneous psychiatric disease with high, increasing prevalence and socio-economic impact.^1^ The serotonergic system is implicated in the etiology and treatment of mood disorders.^2^ Most prescribed antidepressants, the selective serotonin (5-HT) reuptake inhibitors (SSRI) and the dual 5-HT and norepinephrine reuptake inhibitors block physiological reuptake mechanisms in serotonergic axons and thereby increase extracellular 5-HT concentration to activate postsynaptic 5-HT receptors required for clinical effects^3^. However, this process is severely compromised by the simultaneous activation of somatodendritic 5-HT~1A~-autoreceptors in the midbrain raphe nuclei after serotonin transporter (SERT) blockade or MAO inhibition^4,5^. 5-HT~1A~-autoreceptor activation reduces serotonergic activity and forebrain 5-HT release, an effect contrary to that required for the therapeutic response.^3--6^

Hence, the limited clinical efficacy of 5-HT-enhancing drugs and their delayed action are partly due to this negative feedback mechanism. Upon chronic treatment, 5-HT~1A~-autoreceptors desensitize, leading to the recovery of serotonergic activity and 5-HT release.^3,6^ Individuals with elevated density or activity of 5-HT~1A~-autoreceptors are more susceptible to mood disorders and respond poorly to antidepressants.^7--9^

5-HT~1A~R antagonists might thus be useful to improve antidepressant therapy by preventing the 5-HT~1A~-autoreceptor-mediated negative feedback. However, the activation of postsynaptic 5-HT~1A~R is a necessary step for antidepressant effects^6^ which limits the usefulness of this strategy. Thus, unlike the non-selective 5-HT~1A~R/ß-adrenoceptor antagonist pindolol^10-12^ (with a preferential action at 5-HT~1A~-autoreceptors), the selective 5-HT~1A~R antagonist DU-125530 does not enhance clinical fluoxetine effects despite augmenting the presynaptic effects of SSRI.^13^ Overall, these observations have led to the development of antidepressant drugs combining SERT inhibition with partial agonist effects on 5-HT~1A~-R, such as vilazodone^14^ or vortioxetine (the latter compound is also antagonist at other 5-HT receptors^15^).

In recent years we have used a new antidepressant strategy, based on the use of small interfering RNA (siRNA) targeted to serotonin neurons, to selectively reduce the expression and function of presynaptic (but not postsynaptic) 5-HT~1A~R. Local siRNA application in the raphe nuclei of mice reduced the expression and function of 5-HT~1A~ autoreceptors locally, without affecting postsynaptic 5-HT~1A~R. This resulted in an antidepressant-like effect in the forced-swim and tail suspension tests, associated to an enhanced forebrain 5-HT release.^16^

We also developed a conjugated 5-HT~1A~R siRNA (C-1A-siRNA) directed to serotonin neurons, by covalently binding 5-HT~1A~R siRNA molecules to the SSRI sertraline. The intracerebroventricular or intranasal application of the C-1A-siRNA produced a selective reduction of 5-HT~1A~ autoreceptor expression/function without affecting postsynaptic 5-HT~1A~R. This effect was associated to an antidepressant-like effect. Likewise, SSRI administration to C-1A-siRNA-treated mice produced a greater elevation of extracellular 5-HT than in control mice.^17^

Overall, existing evidence indicates that pre- and postsynaptic 5-HT~1A~-R play a major role in antidepressant action, either by limiting (presynaptic 5-HT~1A~ autorecepors) or facilitating their effects (postsynaptic 5-HYT~1A~-R).
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